Objectives: To investigate the relative performance of hip prosthesis constructs as compared with the best performing prosthesis constructs and illustrate the substantial variability in performance of currently used prostheses.
Design: A non-inferiority study.
Setting: The National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR).
Participants: All patients with a primary total hip replacement registered in the NJR between 1 April 2003 and 31 December 2016.
Main outcome measures: Kaplan-Meier failure function for hip prosthesis constructs. Failure difference between best performing construct and remaining constructs.
Methods: Using a non-inferiority analysis, the performance of hip prosthesis constructs by brand were compared with the best performing contemporary construct. Construct failure was estimated using the 1-Kaplan-Meier survival function method, that is, an estimate of net failure. The difference in failure between the contemporary benchmark and all other constructs was tested.
Results: Of the 4442 constructs used, only 134 had ≥500 procedures at risk at 3 years postprimary, 89 of which were not demonstrated to be inferior to the benchmark by at least 100% relative risk. By 10 years postprimary, there were 26 constructs with ≥500 at risk, 13 of which were not demonstrated to be inferior by at least 20% relative risk.Even fewer constructs were not inferior to the benchmark when analysed by age and gender. At 5 years postprimary, there were 15 constructs in males and 11 in females, aged 55-75 years, not shown to be inferior.
Conclusions: There is great variability in construct performance and the majority of constructs have not been demonstrated to be non-inferior to contemporary benchmarks. These results can help to inform patients, clinicians and commissioners when considering hip replacement surgery.
Keywords: benchmarking; hip arthroplasty; medical devices; national joint registry; non-inferiority.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.